Antitumor agent 2

Antitumor agent-2 has anti-inflammatory and anti-tumor activity and can be used to study cancer.

Antitumor agent-200 (Compound 2g) is a microtubule synthesis inhibitor that binds to the colchicine site on tubulin, causing G2/M cell cycle arrest and inducing reactive oxygen species (ROS) production. It demonstrates significant inhibitory activity against P-glycoprotein (P-gp) overexpressing cell lines MCF7/ADR and KBV200, with resistance indices (DRI) of 0.83 and 0.58, respectively. In an MCF-7 xenograft model, Antitumor agent-200 (at 25 mg/kg, administered intraperitoneally) achieves a 57.2% tumor growth inhibition rate. This compound is applicable for research in the field of cancer therapy.

Antitumor agent-202 is a stabilizer of the p53Y220C mutant, selectively inhibiting the proliferation of tumor cells carrying the p53Y220C mutation. It is applicable for research focused on cancers associated with the p53 Y220C mutation.

Antitumor agent-201 (Compound 10) is a Golgi apparatus-targeting chloride ion transport activator with an EC50 for promoting transmembrane chloride ion transport of 1.53 mol% and an IC50 against HepG2 cells of 7.13 μM. By selectively acting on the Golgi apparatus, Antitumor agent-201 disrupts chloride ion homeostasis, decreases the expression of key proteins such as GM130 and GRASP55, and alters Golgi structure and function. This process induces Golgi apparatus autophagy, triggers apoptosis in cancer cells, and causes cell cycle arrest at the G2/M phase, thereby exhibiting anticancer activity. Antitumor agent-201 is applicable for research in the field of cancer-related diseases.

Antitumor agent-204 (compound 15a) is a potent antitumor drug with cytotoxic properties. It induces the release of nitric oxide (NO) and the production of reactive oxygen species (ROS). Additionally, Antitumor agent-204 triggers apoptosis and causes cell cycle arrest at the G2/M phase, demonstrating significant antitumor activity.

Antitumor agent-203 (compound 26) is a derivative of Exatecan (DX-8951) and serves as an ADC cytotoxin for antibody-drug conjugate (ADC) preparation.

Antitumor agent-209 (Compound 10g), a quinoline derivative, functions as an antineoplastic agent. It effectively inhibits the proliferation of various cancer cell lines, specifically HCT-116, RKO, DLD1, HepG2, BGC-823, NCI-H1650, and SK-OV-3, with IC50 values of 0.37, 0.58, 0.81, 0.79, 0.89, 0.78, and 0.89 μM, respectively.

Antitumor agent-208, an analog of Bufalin, is a potent and orally active antitumor agent. It exhibits antiproliferative activity against tumor cell lines with an IC50 of 0.30-1.09 nM. In MV-4-11 xenograft mouse models, Antitumor agent-208 inhibits tumor growth. It is applicable in cancer research, including studies on acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC).

Antitumor agent-205 (compound 9) is an Ecteinascidin derivative and an antitumor agent. It exhibits antiproliferative activity against A549 and HT29 cells, with a GI50 value of 16.4 nM for both cell lines. Antitumor agent-205 is applicable in the study of lung and colon cancer.

Antitumor agent-21 (TRX818) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities.

Antitumor agent-28 is a compound that specifically targets and inhibits the activity of the ataxia telangiectasia mutated (ATM) kinase. By doing so, it effectively impedes the progression of ATM-mediated diseases and demonstrates significant anti-cancer activity.

Antitumor agent-23 exhibits potent antitumoral activity, as demonstrated by its GI50 values of 38, 48, 5, 27, 80, and 28 nM against the lymphoma cell lines GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI respectively.

Antitumor agent-29 is a hepatocyte-targeting prodrug with demonstrated efficacy and minimal toxicity in anticancer applications.

Bestatin (Ubenimex) competitively inhibits many aminopeptidases, including B, N and leucine aminopeptidases. Ubenimex is a microbial metabolite and dipeptide with potential immunomodulatory and antitumor activities. Aminopeptidases has been implicated in the process of cell adhesion and invasion of tumor cells. Therefore, inhibiting aminopeptidases may partially attribute to the antitumor effect of ubenimex. This agent also activates T lymphocyte, macrophage, and bone marrow stem cell as well as stimulates the release of interleukin-1 and -2, thus further enhances its antitumor activity.

VK3-OCH3 (2-[(2-Methoxy)ethylthio]-3-methyl-1,4-na) is a selective antitumor agent via heme oxygenase (HO-1) related mechanisms; Vitamine K3 analogue.

2'-Deoxy-2'-fluoro-beta-D-arabinoguanosine is a purine nucleoside analog with a broad spectrum of antitumor activity, targeting malignant tumors of the inert lymphatic system and inducing apoptosis. The anticancer mechanism of 2'-Deoxy-2'-fluoro-beta-D-arabinoguanosine is dependent on the inhibition of DNA synthesis.

4-(Benzo[d]oxazol-2-yl)aniline is a potent antitumor agent with inhibitory activity against mammary carcinoma cell lines [1].

Chromomycin A3 is an antibiotic produced by Streptomyces sp that binds to gc-rich DNA sequences in the presence of divalent cations and inhibits DNA replication and transcription; it is also used as a fluorescent DNA stain and assay; and it has anticancer activity against diseases such as Hodgkin's, lung adenocarcinomas, melanomas, and breast cancer.

JI051 is an antitumor agent that interacts with the cancer-associated protein chaperone prohibitin 2 (PHB2) to induce cell cycle arrest by inhibiting the transcription of the Notch downstream effector gene, Hes1, and inhibits the proliferation of HEK293 cells and pancreatic cancer cells.

Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.) , shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.

Actinonin is a natural antibacterial agent produced by Streptomyces, also serving as an effective PDF (peptide deformylase) inhibitor and apoptosis inducer. It inhibits APN (Aminopeptidase N), MMPs and heparin α, exhibiting antiproliferative and antitumour activity.

ar-Turmerone is a natural volatile organic compound extracted from the rhizomes of turmeric (Curcuma longa). ar-Turmerone exhibits oral bioavailability and possesses biological activities such as antitumor, anti-inflammatory, antioxidant, and neuroprotective effects. ar-Turmerone exerts a positive regulatory effect on dendritic cells in mice. Ar-turmerone can induce neural stem cell proliferation both in vitro and in vivo, making it useful for research on neurological disorders. Ar-turmerone induces apoptosis in U937 cells.

CB 300919 is a quinazoline-based antitumor agent exhibiting high activity against CH1 human ovarian tumor xenografts, with continuous exposure (96 h) resulting in a growth inhibition (IC50: 2 nM).

Duocarmycin A, an antitumor antibiotic, is a DNA alkylator and efficiently alkylates adenine N3 at the 3′ end of AT-rich sequences in the DNA. Duocarmycin A, as a chemotherapeutic agent, results in HLC-2 cells typically apoptotic changes.